Truist Financial Issues Pessimistic Forecast for Medtronic (NYSE:MDT) Stock Price

Medtronic (NYSE:MDT) had its target price decreased by equities researchers at Truist Financial from $107.00 to $103.00 in a research note issued to investors on Wednesday,MarketScreener reports. The brokerage currently has a “hold” rating on the medical technology company’s stock. Truist Financial’s price target suggests a potential upside of 6.32% from the company’s previous close.

MDT has been the topic of several other reports. Mizuho upgraded shares of Medtronic to a “strong-buy” rating in a report on Wednesday. Barclays reiterated an “overweight” rating and issued a $118.00 target price on shares of Medtronic in a report on Wednesday. CICC Research started coverage on Medtronic in a research report on Friday, January 30th. They issued an “outperform” rating on the stock. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. Finally, Royal Bank Of Canada upped their target price on Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $110.84.

Medtronic Stock Performance

NYSE:MDT traded down $0.70 during midday trading on Wednesday, reaching $96.88. 7,188,103 shares of the company traded hands, compared to its average volume of 9,104,671. Medtronic has a twelve month low of $79.55 and a twelve month high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The company has a fifty day moving average price of $99.04 and a 200 day moving average price of $96.65. The firm has a market capitalization of $124.20 billion, a price-to-earnings ratio of 26.99, a price-to-earnings-growth ratio of 2.45 and a beta of 0.71.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.The business’s revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, analysts expect that Medtronic will post 5.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Medtronic

Several large investors have recently made changes to their positions in the company. Brighton Jones LLC boosted its holdings in Medtronic by 1,368.0% during the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after buying an additional 37,265 shares during the last quarter. Sivia Capital Partners LLC raised its stake in shares of Medtronic by 9.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after purchasing an additional 381 shares in the last quarter. Brookstone Capital Management lifted its stake in Medtronic by 12.4% in the 2nd quarter. Brookstone Capital Management now owns 22,772 shares of the medical technology company’s stock valued at $1,985,000 after purchasing an additional 2,509 shares during the last quarter. R Squared Ltd bought a new position in Medtronic during the second quarter worth $474,000. Finally, Asset Management One Co. Ltd. lifted its position in Medtronic by 1.9% during the second quarter. Asset Management One Co. Ltd. now owns 575,592 shares of the medical technology company’s stock worth $50,174,000 after acquiring an additional 10,458 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Regulatory/coverage win in Japan for Medtronic’s Symplicity Spyral renal denervation device and management commentary that the company is investing in rollout and hiring to support market development — supports revenue upside from a growing hypertension therapy. Medtronic’s blood pressure device wins coverage nod in Japan
• Positive Sentiment: Analyst upgrade: Mizuho moved Medtronic to a “strong-buy,” which can support buying interest and short-term momentum. Mizuho upgrade reported via Zacks
• Neutral Sentiment: Industry growth tailwinds — a separate report highlights expansion in non‑invasive therapies (HIFU) and robotics/image‑guided systems; positive for device sector demand but not a direct Medtronic headline. HIFU Market Competitive Landscape Report 2025
• Neutral Sentiment: Competitive update — Intuitive Surgical (ISRG) reports faster international procedure growth, which underscores competitive dynamics in robotics and could pressure Medtronic’s robotics expectations over time. ISRG’s International Growth Outpaces US
• Neutral Sentiment: Company commentary and Q3 earnings materials are out (transcript available) showing mixed results: solid robotics wins but offset by some legal and expense items — provides context for guidance and valuation debate. Medtronic (MDT) Q3 2026 Earnings Call Transcript
• Negative Sentiment: Multiple broker notes lowered expectations or targets (JPMorgan, Robert W. Baird; Leerink cut its target to $119) — analyst downgrades/target cuts weigh on sentiment and can amplify selling. JPMorgan low expectations
• Negative Sentiment: Planned layoffs: Medtronic will cut 81 roles at a California diabetes site as it readies the diabetes spin‑out; restructuring adds near‑term execution risk and uncertainty around the separations. Medtronic to cut 81 employees at California diabetes site
• Negative Sentiment: Broader skepticism in media pieces discussing mixed quarterly results, legal exposure and whether recent wins materially change Medtronic’s investment case — fuels analyst disagreement and investor caution. Mixed Q3 Results, Robotics Win and Legal Hit

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).